As shown in Figure 6B, TP-0903 treatment did not affect the percentage of CD3-positive cells in CD45+ cells infiltrating the tumor tissue, but TP-0903 plus WIN55212-2 treatment significantly increased the proportion of CD3+ cells compared to the control group (p ≤ 0.05). The gene discussed is PTPRC; the disease is neoplasm.